Researches have identified molecular features of testicular germ cell cancers that could inform future efforts to improve treatment decisions and help monitor patients to see if their cancer has come back.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
Scientists have made the first direct observation of a key step in the process that bacteria use to rapidly evolve new traits, including antibiotic resistance.
Non-profit Bill & Melinda Gates Medical Research Institute (MRI) has officially been launched, creating a new vision for drug development with a clear focus on the millions of people that die annually from contracting malaria, tuberculosis and diarrheal diseases.
Despite the availability of hepatitis C treatment and changes in restrictions of these therapies, private insurance companies and even public payers like Medicaid and Medicare are still refusing to pay for it.
FDA commissioner, Scott Gottlieb said that he expects the FDA to approve 40 gene therapies by 2022 in a fireside chat at the 2018 BIO International Convention.
Researchers have synthesized the first artificial human prion, a dramatic development in efforts to combat a devastating form of brain disease that has so far eluded treatment and a cure.
Microbiotica has entered into a multi-year strategic collaboration with Genentech, a Roche company, to discover, develop, and commercialise biomarkers, targets, and medicines for inflammatory bowel disease.
The genomes of more than 3000 of these bacteria have been mapped by scientists in order to better understand diseases and the mechanisms of antibiotic resistance.
A new study provides a unique look at a novel strategy — clinical trials in a dish — that bridges preclinical testing and clinical trials.
Sometimes a new company catches the eye, and this week that company is nference, a Cambridge MA-based start-up developing AI technology to discover and develop drugs more effectively. AI is no longer new in this space, so why does nference grab our attention?